DL
TCRT icon

Daniel Loeb’s Alaunos Therapeutics TCRT Stock Holding History

Daniel Loeb’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,000
Closed -$23.4M – 47
2015
Q2 		$23.4M Buy
+13,000
New +$20.2M 0.22% 43

Other funds holding TCRT

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Daniel Loeb's TCRT Position: Q3 2015 in Review

Daniel Loeb sold out of Alaunos Therapeutics (TCRT) in Q3 2015, closing a stake of 13,000 shares — an estimated $23.4M sold.

Daniel Loeb first reported a position in TCRT in Q2 2015 and held it in 1 quarter. The position peaked at $23.4M in Q2 2015. 138 funds tracked by Wall St. Rank hold TCRT as of Q3 2015.

  • Daniel Loeb reported no remaining Alaunos Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Daniel Loeb sold 13,000 Alaunos Therapeutics shares in Q3 2015, an estimated $23.4M.
  • Daniel Loeb first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 1 quarter.
  • Daniel Loeb's Alaunos Therapeutics position peaked at $23.4M in Q2 2015.
  • 138 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2015.

Based on Third Point's 13F filing for Q3 2015, filed 13 Nov 2015.